Noninvasive Detection of Response and Resistance in <i>EGFR</i> -Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA
Geoffrey R. Oxnard(Foundation Medicine (United States)), Pasi A. Jänne(Harvard University), Paul T. Kirschmeier(Brigham and Women's Hospital), Stacy L. Mach(Brigham and Women's Hospital), Melissa M. Messineo(Brigham and Women's Hospital), Cloud P. Paweletz(Massachusetts General Hospital), Jason J. Luke(University of Chicago), David M. Jackman(Brigham and Women's Hospital), Yanan Kuang(Dana-Farber Cancer Institute), Allison O’Connell(Brigham and Women's Hospital), Mohit Butaney(Brigham and Women's Hospital)
Cited by 781
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k